Niki BioSolutions, Inc. (NIKI) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
Relative to the broader market, NIKI trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NIKI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NIKI Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
NIKI P/E vs Peers
Closest public peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 216.1 | - | -94% | |
| $3B | 148.0 | - | +1082%Best | |
| $5B | 15.8Lowest | - | -14% | |
| $16B | 408.0 | - | -1555% | |
| $45B | 32.6 | 0.80Best | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
NIKI Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NIKI — Frequently Asked Questions
Quick answers to the most common questions about buying NIKI stock.
What is NIKI's P/E ratio?
Niki BioSolutions, Inc. (NIKI) trailing twelve-month P/E ratio is -0.1x, based on TTM diluted EPS of N/A. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is NIKI stock overvalued or undervalued?
NIKI current P/E: -0.1x. 5-year average P/E: N/A. Percentile: N/A.
Is NIKI stock expensive?
NIKI is fairly valued relative to its own history. The current P/E of -0.1x is near the 5-year average of N/A (N/A percentile of historical range).
What is NIKI's historical P/E range?
Over the past 5 years, NIKI's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -0.1x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does NIKI's P/E compare to the S&P 500?
NIKI trades at -0.1x P/E versus the S&P 500 median of 21.8x. The 100% discount to the market suggests lower growth expectations or perceived higher risk.
How does NIKI's valuation compare to sector peers?
Niki BioSolutions, Inc. P/E of -0.1x can be benchmarked against sector peers in the comparison table on this page.
What is NIKI's PEG ratio?
NIKI PEG ratio is N/A, based on a P/E of -0.1x and EPS growth of 75.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is NIKI's earnings yield?
NIKI earnings yield is N/A, the inverse of its -0.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.